ALK Reports Strong Q3 2025 Financial Results
ALK-Abelló A/S has reported an impressive 18% global organic revenue growth in Q3, with operating profit rising by 41%.
This positive momentum reflects strong performance across various product lines, notably tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. The increase in operating profit can be attributed to notable sales growth, improved gross margins, and recent optimizations, leading to a profit margin that soared to 28%. ALK has also upgraded its full-year outlook based on these strong results.
Performance Highlights for Q3
The comparative figures for the third quarter in the year prior are included for context.
- Total revenue surged by 18% reaching DKK 1,530 million, compared to DKK 1,313 million last year, buoyed by double-digit sales growth across all regions.
- Tablet sales experienced a healthy growth of 17%, climbing to DKK 737 million, with Europe and North America witnessing growth rates of 23% and 20%, respectively. However, international markets faced a 4% decline, affected by timing of product shipments, though main market sales remained robust.
- Sales from SCIT/SLIT-drops rose by 11% to DKK 557 million, primarily driven by increasing demands in China and France.
- The Other products and services segment saw a remarkable growth of 42%, contributing DKK 236 million, with the anaphylaxis portfolio leading the way with an inspiring 68% growth due to soaring Jext sales.
- Operating profit (EBIT) jumped by 41% to DKK 423 million, resulting in an EBIT margin of 28%, up from 23%. This progress stemmed from enhanced sales, better gross margins, and efficiencies gained from last year's strategic optimization measures.
- Free cash flow amounted to DKK 290 million, driven largely by increased earnings, though cash flow from investment activities posted a negative DKK 96 million.
Financial Overview
Below you'll find key financial highlights that show the progress made by ALK.
Revenue and EBIT Breakdown
- Revenue for Q3 2025 reached 1,530 DKK million with a local currency growth of 18%, while reported currency showed a 17% growth.
- For the first nine months of the year, revenue amounted to 4,579 DKK million with a local currency growth rate of 14% compared to the previous year.
- EBIT increased to 423 DKK million for Q3, representing a 41% growth, while for nine months, the EBIT reached 1,267 DKK million, showing a 44% growth rate.
Allergy+ Strategic Updates
- ALK’s Allergy+ strategy is gaining traction, especially with the positive response to the pediatric rollout of allergy tablets, particularly the house dust mite (HDM) tablet, which is attracting a new patient influx.
- The initiation of a phase 3 bridging trial for ACARIZAX in China, supported by the new partnership with GenSci, aims to advance ALK's HDM product market presence.
- Recently, the EURneffy nasal adrenaline spray was launched in the UK, the largest anaphylaxis market in Europe, with additional launches planned across the continent.
- The Fast Track designation granted by the US FDA to the peanut SLIT-tablet development underlines ALK's commitment to innovation, with phase 2 trial results expected in the upcoming year.
Outlook for 2025
In light of Q3 performance and a positive outlook for the remainder of the fiscal year, ALK has revised its full-year forecast. Expected revenue growth is now projected at 13-15% in local currencies, primarily due to increased volumes as more patients begin receiving ALK’s allergy and anaphylaxis treatments.
- Furthermore, the EBIT margin forecast has been improved to approximately 26%, a reflection of effective revenue growth strategies and ongoing optimizations.
CEO Peter Halling commented on the outcomes: “Q3 demonstrated our successful drive in executing critical growth strategies, especially the rollout of respiratory tablets for young children, which is ahead of schedule. Our confidence in achieving sustained and profitable growth through enhanced patient outreach with evidence-based solutions continues to build.”
For more information, please contact our Investor Relations:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media Inquiries: Maiken Riise Andersen, tel. +45 5054 1434
Frequently Asked Questions
What is the revenue growth reported by ALK for Q3 2025?
ALK reported an impressive revenue growth of 18% in Q3 2025.
What drove the increase in operating profit for ALK?
The increase in operating profit was driven by strong sales growth and improved gross margins.
How did the Allergy+ strategy perform this quarter?
The Allergy+ strategy witnessed strong market response, especially with the pediatric rollout of allergy tablets.
What is the revised full-year revenue outlook for ALK?
ALK has upgraded its full-year revenue outlook to a growth of 13-15% in local currencies.
What new products did ALK launch recently?
ALK recently launched the EURneffy nasal adrenaline spray in the UK and is preparing for additional product launches across Europe.
